Regeneron, US75886F1075

Regeneron stock: FDA approves quarterly Livsayis therapy

Published on 11/19/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron wins FDA approval for Livsayis in antibody-positive generalized myasthenia gravis. The quarterly treatment opens a new commercial neurology opportunity.

FDA approval opens commercial phase

  • Livsayis is approved for adults with AChR-antibody-positive generalized myasthenia gravis.
  • The treatment is administered under the skin four times a year.
  • Alnylam is due a 25 million US dollar milestone payment and may receive royalties of up to 15 percent on global net sales.
Regeneron, US75886F1075, Illustration mit AI erstellt.

Regeneron Pharmaceuticals won U.S. regulatory approval for Livsayis on Wednesday, November 18, 2026, expanding its commercial portfolio with a quarterly treatment for adults with antibody-positive generalized myasthenia gravis. The approval was reported in a Regeneron announcement.

New neurology product reaches market

Livsayis, also known as cemdisiran, is a complement component 5-directed small interfering RNA therapy. It reduces production of C5, a protein involved in terminal complement activation, and is administered by subcutaneous injection four times a year.

The FDA approval covers adults who test positive for antibodies against the acetylcholine receptor, the predominant form of generalized myasthenia gravis. Regeneron described Livsayis as its first approved siRNA therapy and its first approved neurology medicine.

Alnylam receives milestone payment

The treatment originated at Alnylam Pharmaceuticals and became part of the companies' RNA interference collaboration. Regeneron assumed sole responsibility for development, manufacturing and commercialization in 2024. Alnylam is due a 25 million US dollar payment for the approval and may receive tiered royalties reaching up to 15 percent of global net sales.

The FDA decision was based on Phase 3 NIMBLE results. After 24 weeks, the MG-ADL score improved by 4.5 points with Livsayis, compared with 2.2 points with placebo.

Launch execution becomes the focus

Investors will now watch physician adoption, reimbursement and the contribution of Livsayis to Regeneron's rare-disease business. The treatment carries a boxed warning for serious meningococcal infections and is distributed through a restricted safety program.

Regeneron stock traded at 848.90 euros on Lang & Schwarz at 16:37 CET on Thursday, November 19, 2026. The quote was 1.29 percent below the 860.00 euro level recorded at 14:30 CET in the earlier same-day report; this comparison is separate from the Xetra session.

The broader U.S. biotechnology market can be followed through current market reports.

More news and analyses on Regeneron stock.

Regeneron Pharmaceuticals at a glance

  • Company: Regeneron Pharmaceuticals, Inc.
  • ISIN: US75886F1075
  • Ticker: REGN
  • Product: Livsayis (cemdisiran)
  • Indication: Antibody-positive generalized myasthenia gravis in adults
  • Lang & Schwarz quote: 848.90 euros at 16:37 CET on November 19, 2026
Disclaimer...
en | US75886F1075 | REGENERON | boerse | 70537043 | bgmi